CLINICAL_TRIALS ClinicalTrials.gov record update

Furmonertinib Mesylate Neoadjuvant Treatment of Resectable Stage Ⅱ-ⅢB Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor（EGFR）Sensitive Mutation：a Prospective，Muliticenter，Open Label，Phase Ⅱ Single-arm Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05987826
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:38.118411+00:00
Published At: 2023-08-14T00:00:00+00:00
Record Updated At: 2023-08-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Small Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-14"
protocolSection.identificationModule.nctId: "NCT05987826"
protocolSection.identificationModule.officialTitle: "Furmonertinib Mesylate Neoadjuvant Treatment of Resectable Stage \u2161-\u2162B Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor\uff08EGFR\uff09Sensitive Mutation\uff1aa Prospective\uff0cMuliticenter\uff0cOpen Label\uff0cPhase \u2161 Single-arm Study"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.